Sign up for our newsletter!
Your data will be handled in compliance with our privacy policy.
Granted European Patent
Smoltek just received a patent letter of a new granted patent in Europe.
February 22, 2017
“We are happy to see another achievement to our core patent portfolio. Now one of our most strategic patents is also granted in Europe,” says Anders Johansson, Smoltek´s CEO.
Smoltek’s patent portfolio now globally comprises 44 granted patents. Read more about our patents here.
Sign up for our newsletter!
Your data will be handled in compliance with our privacy policy.
Related news and insights
Smoltek has been granted three new patents
Smoltek has been granted three new patents since the start of the year. The patents are related to three different families: Interconnects, Assembly platform and Compact energy storage interposer. This makes our patent portfolio to now comprise 68 granted patents in total.
Smoltek patent No. 63 now granted
Smoltek has yet another patent granted. This time in India. The patent is related to the growth process of nanostructures and it makes the Catalyst diffusion patent family complete.
Helplayer IP-family expands with new granted patent
The constantly expanding Smoltek IP-portfolio is divided into several different patent families. One of them is named Helplayer, a method to protect the underlaying materials when growing nanostructures on a given surface. To this family we can add another patent number recently granted.
New Smoltek patent granted
Smoltek keep growing its proprietary technology platform. In the beginning of May 2020 patent No. 58 was granted. The patent is connected to our helplayer family.
Smoltek patent No. 56 now granted
Smoltek is awarded a new patent. This Korean patent is the second of a patent family in the direction of CNF-MIM based compact energy storage interposers. This means that our patent portfolio now comprises 56 granted patents.
New patent in Smoltek IP-portfolio
Smoltek keep on building its proprietary technology platform through strategic and continuous development of the patent portfolio.